BeyondSpring (BYSI)
(Delayed Data from NSDQ)
$1.94 USD
+0.07 (3.74%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $1.95 +0.01 (0.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.94 USD
+0.07 (3.74%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $1.95 +0.01 (0.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of -4.76% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q1 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings
by Zacks Equity Research
Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%
by Zacks Equity Research
BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Can The Uptrend Continue for BeyondSpring (BYSI)?
by Zacks Equity Research
Investors certainly have to be happy with BeyondSpring Inc. (BYSI) and its short term performance.
BeyondSpring Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BeyondSpring has been struggling lately, but the selling pressure may be coming to an end soon.
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
Why BeyondSpring (BYSI) Could Be a Potential Winner
by Zacks Equity Research
Although overlooked by the investors, BeyondSpring (BYSI) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.